Recent

% | $
Quotes you view appear here for quick access.

Blue Holdings Inc. Message Board

  • blutribe1 blutribe1 Jun 20, 2014 12:35 PM Flag

    3 more large Insider sales this week...Nick Leschly Sells 42,925 Shares of bluebird bio Stock and

    (NASDAQ:BLUE) CEO Nick Leschly sold 42,925 shares of the company’s stock on the open market in a transaction dated Monday, June 16th. The shares were sold at an average price of $40.02, for a total value of $1,717,858.50.
    6/19/14 (NASDAQ:BLUE) COO Jeffrey T. Walsh sold 1,500 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $39.86, for a total transaction of $59,790.00.

    bluebird bio logobluebird bio (NASDAQ:BLUE) Insider Mitchell H. Finer sold 10,000 shares of bluebird bio stock on the open market in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $39.84, for a total transaction of $398,400.00

    bearish for an already overpriced stock, even insiders agree stock overvalued at these levels

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Check out officers' holdings - other than CEO, VERY light.

      • 1 Reply to rosengroup2001
      • well, if they aren't getting some of their compensation in shares, they are going to miss out big time. this sector of biotech is going to heat up ...way up:
        FRANKFURT/LONDON, June 23 (Reuters) - Bayer has struck an alliance with U.S. biotech firm Dimension Therapeutics to develop a gene therapy for the treatment of haemophilia A, marking renewed interest in an approach to tackle the cause of diseases at a cellular level.

        Gene therapy involves inserting corrective genes into malfunctioning cells to get them to work again without further use of drugs. Dimension has been looking into using viruses to carry the genes to the affected cells.

        Gene therapy has seen more than 20 years of experiments and a series of disappointments. However, Amsterdam-based UniQure is about to start selling its gene therapy drug Glybera in Europe as a treatment for the ultra-rare disease lipoprotein lipase deficiency (LPLD) with partner Chiesi.

    • so, what you're saying is you don't know what an auto sale is? so I guess you're also saying you shouldn't be trading stocks.

      • 1 Reply to casuconsulto
      • yeah apparently someone who isn't really a trader but granted stock, then sell it for profit (because why not, right?) indicates a stock is overvalued...

        no, it only indicates that someone took profit and ran, who knows the stock could hit 50-60$, or plus

        ask yourself, if you were in their shoes, would you do the same? i surely would, 60k, 1.2 mil, 400k, i'd take that any day considering i'm working for a company, not really trading for a living, let the traders decide whether it's over-priced or under-priced

 
BLUE
114.41+2.73(+2.44%)Mar 27 4:00 PMEDT